{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T21:28:24Z","timestamp":1786483704384,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016646","name":"HCA Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Orthopaedic Science"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jos.2026.02.002","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:30:36Z","timestamp":1771849836000},"page":"812-818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of glucagon-like peptide-1 receptor agonist on outcomes after elective total hip arthroplasty: A retrospective cohort study"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3291-9700","authenticated-orcid":false,"given":"Troy","family":"Puga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McKenna W.","family":"Box","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Riehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jos.2026.02.002_bib1","unstructured":"Centers for Disease Control and Prevention (CDC). The high obesity program 2023-2028. Accessed March 24, 2024. https:\/\/www.cdc.gov\/hop\/php\/about\/index.html#:∼:text=CDC%20funds%2016%20land%20grant,%2C%20physical%20activity%2C%20and%20obesity."},{"issue":"11","key":"10.1016\/j.jos.2026.02.002_bib2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"10148","key":"10.1016\/j.jos.2026.02.002_bib3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jos.2026.02.002_bib4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.12591","article-title":"Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"18","author":"Nauck","year":"2016","journal-title":"Diabetes Obes Metabol"},{"issue":"3","key":"10.1016\/j.jos.2026.02.002_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreobff","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jos.2026.02.002_bib6","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/dom.14681","article-title":"Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes","volume":"24","author":"Bensignor","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.jos.2026.02.002_bib7","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/art.39707","article-title":"Association between overweight and obesity and risk of clinically diagnosed knee, hip, and hand osteoarthritis: a population-based cohort study","volume":"68","author":"Reyes","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.jos.2026.02.002_bib8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/17453674.2018.1473327","article-title":"Outcomes following hip and knee replacement in diabetic versus nondiabetic patients and well versus poorly controlled diabetic patients: a prospective cohort study","volume":"89","author":"Lenguerrand","year":"2018","journal-title":"Acta Orthop"},{"issue":"24","key":"10.1016\/j.jos.2026.02.002_bib9","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.2106\/JBJS.20.00203","article-title":"Impact of diabetes on 90-Day episodes of care after elective total joint arthroplasty among medicare beneficiaries","volume":"102","author":"Na","year":"2020","journal-title":"J Bone Joint Surg Am"},{"issue":"7","key":"10.1016\/j.jos.2026.02.002_bib10","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1302\/0301-620X.92B7.24461","article-title":"Risk of revision of a total hip replacement in patients with diabetes mellitus: a population-based follow up study","volume":"92","author":"Pedersen","year":"2010","journal-title":"J Bone Joint Surg Br"},{"issue":"3","key":"10.1016\/j.jos.2026.02.002_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150866","article-title":"Patient-related risk factors for periprosthetic joint infection after total joint arthroplasty: a systematic review and meta-analysis","volume":"11","author":"Kunutsor","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jos.2026.02.002_bib12","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.arth.2013.02.011","article-title":"Obesity and total joint arthroplasty: a literature based review","volume":"28","year":"2013","journal-title":"J Arthroplasty"},{"issue":"11","key":"10.1016\/j.jos.2026.02.002_bib13","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/art.42630","volume":"75","author":"Hannon","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.jos.2026.02.002_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.arth.2023.07.017","article-title":"Medical weight optimization for arthroplasty patients: a primer of emerging therapies for the joint arthroplasty surgeon","volume":"39","author":"Mayfield","year":"2024","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.jos.2026.02.002_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.artd.2024.101327","article-title":"Glucagon-like peptide Receptor-1 agonists used for medically-supervised weight loss in patients with hip and knee osteoarthritis: critical considerations for the arthroplasty surgeon","volume":"27","author":"Heckmann","year":"2024","journal-title":"Arthroplast Today"},{"issue":"9S1","key":"10.1016\/j.jos.2026.02.002_bib16","first-page":"S259","article-title":"Utilization of glucagon-like Peptide-1 receptor agonist at the time of total hip arthroplasty for patients who have morbid obesity","volume":"40","author":"Kim","year":"2024","journal-title":"J Arthroplasty"},{"issue":"6","key":"10.1016\/j.jos.2026.02.002_bib17","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.arth.2024.10.099","article-title":"Glucagon-like Peptide-1 receptor agonist use is not associated with increased complications after total hip arthroplasty in patients who have type 2 diabetes","volume":"40","author":"Heo","year":"2024","journal-title":"J Arthroplasty"},{"issue":"3","key":"10.1016\/j.jos.2026.02.002_bib18","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.arth.2023.12.023","article-title":"Semaglutide use prior to total hip arthroplasty results in fewer postoperative prosthetic joint infections and readmissions","volume":"39","author":"Magruder","year":"2024","journal-title":"J Arthroplasty"},{"issue":"12","key":"10.1016\/j.jos.2026.02.002_bib19","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1016\/j.arth.2024.05.079","article-title":"Decreased risk of readmission and complications with preoperative GLP-1 analog use in patients undergoing primary total joint arthroplasty","volume":"39","author":"Buddhiraju","year":"2024","journal-title":"J Arthroplasty"},{"issue":"21","key":"10.1016\/j.jos.2026.02.002_bib20","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.5435\/JAAOS-D-24-01284","article-title":"The effects of glucagon-like Peptide-1 agonist therapy on risk of infection, fracture, and early revision in primary total joint arthroplasty","volume":"33","author":"Levidy","year":"2025","journal-title":"J Am Acad Orthop Surg"},{"issue":"4","key":"10.1016\/j.jos.2026.02.002_bib21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.jos.2026.02.002_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"10.1016\/j.jos.2026.02.002_bib23","series-title":"The epidemiology and outcomes of critical illness in Manitoba","author":"Garland","year":"2012"},{"issue":"9","key":"10.1016\/j.jos.2026.02.002_bib24","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1097\/CORR.0000000000001772","article-title":"The charlson and elixhauser scores outperform the American society of anesthesiologists score in assessing 1-year mortality risk after hip fracture surgery","volume":"479","author":"Varady","year":"2021","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"10.1016\/j.jos.2026.02.002_bib25","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.arth.2017.08.032","article-title":"Discriminative ability of elixhauser's comorbidity measure is superior to other comorbidity scores for inpatient adverse outcomes after total hip arthroplasty","volume":"33","author":"Ondeck","year":"2018","journal-title":"J Arthroplasty"},{"issue":"5","key":"10.1016\/j.jos.2026.02.002_bib26","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.arth.2019.01.044","article-title":"A weighted index of elixhauser comorbidities for predicting 90-day readmission after total joint arthroplasty","volume":"34","author":"Goltz","year":"2019","journal-title":"J Arthroplasty"},{"issue":"3","key":"10.1016\/j.jos.2026.02.002_bib27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/CORR.0000000000000615","article-title":"Is obesity associated with increased risk of deep vein thrombosis or pulmonary embolism after hip and knee arthroplasty? A large database study","volume":"477","author":"Sloan","year":"2019","journal-title":"Clin Orthop Relat Res"},{"issue":"3","key":"10.1016\/j.jos.2026.02.002_bib28","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/ALN.0b013e3181979440","article-title":"Development and validation of an acute kidney injury risk index for patients undergoing general surgery: results from a national data set","volume":"110","author":"Kheterpal","year":"2009","journal-title":"Anesthesiology"},{"issue":"7","key":"10.1016\/j.jos.2026.02.002_bib29","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2106\/JBJS.H.00116","article-title":"The impact of glycemic control and diabetes mellitus on perioperative outcomes after total joint arthroplasty","volume":"91","author":"Marchant","year":"2009","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.jos.2026.02.002_bib30","first-page":"422","article-title":"Higher patient complexities are associated with increased length of stay, complications, and readmissions after total hip arthroplasty","volume":"38","author":"Guntaka","year":"2021","journal-title":"Surg Technol Int"},{"issue":"18","key":"10.1016\/j.jos.2026.02.002_bib31","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jos.2026.02.002_bib32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.japh.2023.10.002","article-title":"Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022","volume":"64","author":"Watanabe","year":"2024","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.jos.2026.02.002_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.arth.2025.07.015","article-title":"The impact of glucagon-like Peptide-1 receptor agonist use on clinical outcomes after total hip and knee arthroplasty: a systematic review and meta-analysis of 346,899 patients","author":"Lee","year":"2025","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.jos.2026.02.002_bib34","article-title":"Association of preoperative GLP-1 receptor agonist use with outcomes after primary total knee arthroplasty","author":"Box","year":"2025","journal-title":"Knee"},{"issue":"12","key":"10.1016\/j.jos.2026.02.002_bib35","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.arth.2025.06.083","article-title":"The association between glucagon-like Peptide-1 receptor agonists and postoperative complications after arthroplasty: a systematic review and meta-analysis","volume":"40","author":"Chan","year":"2025","journal-title":"J Arthroplasty"},{"issue":"2s","key":"10.1016\/j.jos.2026.02.002_bib36","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.1016\/j.arth.2018.09.045","article-title":"Hip and knee section, what is the definition of a periprosthetic joint infection (PJI) of the knee and the hip? Can the same criteria be used for both joints?: proceedings of international consensus on orthopedic infections","volume":"34","author":"Shohat","year":"2019","journal-title":"J Arthroplasty"},{"issue":"9","key":"10.1016\/j.jos.2026.02.002_bib37","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.arth.2020.04.073","article-title":"Reasons and risk factors for 30-Day readmission after outpatient total knee arthroplasty: a review of 3015 cases","volume":"35","author":"Bovonratwet","year":"2020","journal-title":"J Arthroplasty"},{"issue":"9","key":"10.1016\/j.jos.2026.02.002_bib38","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.arth.2013.06.032","article-title":"Incidence of and risk factors for 30-Day readmission following elective primary total joint arthroplasty: analysis from the ACS-NSQIP","volume":"28","author":"Pugely","year":"2013","journal-title":"J Arthroplasty"},{"issue":"3","key":"10.1016\/j.jos.2026.02.002_bib39","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.arth.2017.09.038","article-title":"Association between body mass index and thirty-day complications after total knee arthroplasty","volume":"33","author":"George","year":"2018","journal-title":"J Arthroplasty"}],"container-title":["Journal of Orthopaedic Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0949265826000266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0949265826000266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:39:10Z","timestamp":1786480750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0949265826000266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0949265826000266"],"URL":"https:\/\/doi.org\/10.1016\/j.jos.2026.02.002","relation":{},"ISSN":["0949-2658"],"issn-type":[{"value":"0949-2658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of glucagon-like peptide-1 receptor agonist on outcomes after elective total hip arthroplasty: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Orthopaedic Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jos.2026.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Japanese Orthopaedic Association. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}